Bruker (NASDAQ:BRKR) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Bruker (NASDAQ:BRKR) released its quarterly earnings data on Tuesday. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01), Briefing.com reports. The business had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s revenue was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 EPS. Bruker updated its FY 2024 guidance to 2.360-2.410 EPS and its FY24 guidance to $2.36-2.41 EPS.

Bruker Price Performance

Shares of Bruker stock traded down $1.76 during midday trading on Wednesday, hitting $59.58. 611,984 shares of the company traded hands, compared to its average volume of 1,065,108. The firm’s fifty day moving average price is $64.08 and its 200-day moving average price is $66.56. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.75 and a current ratio of 1.65. Bruker has a 12 month low of $54.55 and a 12 month high of $94.86. The stock has a market cap of $9.02 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 2.32 and a beta of 1.20.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is presently 8.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BRKR shares. TD Cowen dropped their price target on shares of Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research note on Wednesday, August 7th. Wells Fargo & Company reduced their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday. Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Barclays cut their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group cut their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.